Indoco Remedies Ltd. Share Price

Indoco Remedies Clears UK-MHRA Inspection at Goa Plant

Indoco Remedies said its Plant I solid-dosage manufacturing facility in Goa successfully completed a UK Medicines and Healthcare Products Regulatory Agency (UK-MHRA) inspection conducted from September 7 to September 9, 2026. The inspection concluded with no critical or major observations, marking a positive regulatory outcome for the company. The Goa facility supplies regulated markets including the UK, Europe, South Africa, New Zealand, Australia and Canada, and contributes around 30% of Indoco’s international business. The plant manufactures solid and liquid dosage products and holds multiple international regulatory certifications, including USFDA, TGA Australia, EU Malta, WHO-GMP and SAHPRA approvals. The positive UK-MHRA outcome comes shortly after a separate USFDA inspection of Indoco’s Plant II sterile facility in Goa, conducted from August 27 to September 4, which resulted in seven observations. The company is therefore likely to remain under investor focus as the market assesses the regulatory status and quality-compliance trajectory across its manufacturing facilities. Indoco Remedies shares closed at around ₹263.02 on September 11, according to market data, after gaining during the session. The successful UK-MHRA inspection is a positive development for the company’s international operations, although investors will continue to monitor the company’s response to the USFDA observations and their potential impact on regulated-market supplies.

See More

Indoco Remedies Ltd. is a fully integrated pharmaceutical

Strengths Integrated pharma model: Indoco operates across finished dosage formulations and APIs, supported by manufacturing and R&D capabilities. Strong domestic franchise: The company has an established Indian formulation business with a large field force and physician relationships. International footprint: Products are marketed across 55 countries, providing geographical diversification. Regulated-market capabilities: Manufacturing facilities have obtained international regulatory approvals/certifications, supporting exports to regulated markets. Weaknesses FY26 profitability remained under pressure: Consolidated FY26 profit before tax was negative, despite higher operating income. Higher finance costs: FY26 consolidated finance cost increased to approximately ₹122 Cr, from ₹66 Cr in FY25. International sales have historically shown volatility, making export growth less predictable. Opportunities US generics: Additional ANDA approvals and product launches can strengthen the international business. Regulated-market expansion: UK, Europe, Australia, Canada and other regulated markets offer opportunities for higher-value exports. Domestic chronic and specialty segments: Expansion into chronic/sub-chronic and specialty products can improve the domestic product mix. Threats USFDA and other regulatory risks remain a major monitorable. In September 2026, USFDA inspected Goa Plant II and issued seven Form 483 observations; the eventual regulatory outcome will be important to watch. Generic-drug price erosion and intense competition can pressure margins. Competition from Indian and international pharmaceutical manufacturers. API/raw-material price volatility can affect manufacturing margins. Currency fluctuations can affect export earnings. Regulatory delays or remediation costs could affect international growth.

See More

Indoco Remedies Ltd — SWOT Analysis INDOCO Pharmaceuticals

Strengths Established pharmaceutical franchise: Indoco has around 70 years of presence in the Indian pharmaceutical market. Integrated business model: The company operates across formulations and APIs, providing greater control over its pharmaceutical value chain. Strong international presence: Products are marketed across 55 countries, giving the company geographic diversification. Weaknesses Consolidated losses: FY2025–26 consolidated total income increased to ₹1,848.65 crore, but the company reported a ₹98.67 crore net loss before OCI. High finance costs: Consolidated finance cost increased to approximately ₹122.25 crore in FY2025–26 from ₹66.23 crore in FY2024–25. Profitability pressure: Despite higher operating income, the company continued to report losses, indicating pressure on overall profitability. Opportunities Growth in domestic pharmaceuticals: India's expanding healthcare requirements can support continued demand for branded and generic medicines. International expansion: Presence in 55 countries provides scope to increase exports and expand existing product portfolios. New product development: Its research infrastructure and scientific workforce can support development of differentiated formulations and APIs. Margin recovery: Improving manufacturing efficiency, product mix and operating leverage could provide an opportunity for profitability improvement. Threats Regulatory risk: Pharmaceutical companies face stringent regulatory requirements across India and international markets. Pricing pressure: Competition in generic and branded-generic medicines can restrict price increases and put pressure on margins. Rising finance costs: Elevated borrowing costs can continue to affect profitability if debt and finance expenses remain high.

See More

Q1FY27 Quarterly Result Announced for Indoco Remedies Ltd.

SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 Q1FY27 Quarterly Result Announced for Indoco Remedies Ltd.

Pharmaceuticals company Indoco Remedies announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations for Q1FY27 stood at Rs 46,622 lakh, representing a growth of 2.26% QoQ from Rs 45,590 lakh in Q4FY26 and a 8.21% increase YoY compared to Rs 43,086 lakh in Q1FY26. Total Income for the quarter Q1FY27 was Rs 46,968 lakh, showing a marginal decrease of 1.24% QoQ from Rs 47,557 lakh in Q4FY26, and rising 6.43% YoY from Rs 44,130 lakh in Q1FY26. The company reported a Net Profit of Rs 6,544 lakh in Q1FY27, marking a recovery compared to a loss of Rs 2,368 lakh in Q4FY26 and a loss of Rs 3,635 lakh in Q1FY26. Earnings per share (EPS) for Q1FY27 was Rs 7.09, compared to Rs (2.57) in Q4FY26 and Rs (3.94) in Q1FY26. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

See More

Indo Count Industries Ltd. – SWOT Analysis

Strengths (S) Global Leadership in Bed Linen One of India's largest exporters of bed linen and a leading supplier to major retailers in the US and other international markets. Majority of revenue comes from exports, providing access to large international markets and premium customers. Healthy Financial Performance Weaknesses (W) Dependence on Export Markets Significant reliance on the US market exposes the company to demand fluctuations and economic slowdowns overseas. Opportunities (O) China+1 Sourcing Shift Global retailers continue to diversify sourcing away from China, creating opportunities for Indian textile exporters. Expansion of Branded Business Growth in owned brands and direct-to-consumer channels can improve margins. Increasing Global Demand Rising demand for premium bedding and home textile products in developed markets. Threats (T) Global Economic Slowdown Weak consumer spending in the US and Europe may impact order volumes. Intense Competition Competition from domestic manufacturers and low-cost exporting countries. Trade and Tariff Risks Positives: Strong export franchise, integrated manufacturing, global customer base, and benefits from the China+1 sourcing trend. Concerns: Dependence on export markets, currency fluctuations, and raw material price volatility. Disclaimer This SWOT Analysis is prepared solely for educational and informational purposes and should not be construed as investment advice or a recommendation to buy, sell, or hold any security. Investors should conduct their own due diligence and consult a SEBI-registered investment adviser before making investment decisions. SEBI Registration No.: INH000013174.

See More

Update for investors of

is currently trading at Rs. 211.00, up by 7.25 points or 3.56% from its previous closing of Rs. 203.75 on the BSE. The scrip opened at Rs. 216.00 and has touched a high and low of Rs. 220.20 and Rs. 208.55 respectively. So far 28700 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 348.10 on 17-Jul-2025 and a 52 week low of Rs. 163.70 on 30-Mar-2026. Last one week high and low of the scrip stood at Rs. 270.00 and Rs. 191.00 respectively. The current market cap of the company is Rs. 1958.22 crore. The promoters holding in the company stood at 58.86%, while Institutions and Non-Institutions held 19.09% and 22.04% respectively. Indoco Remedies has received EU GMP certification from the German Health Authority (Berlin) for its Oral Solid Dosage (OSD) manufacturing facility (Plant III) located at Baddi, Himachal Pradesh. The inspection was carried out from April 22, 2026, to April 27, 2026. This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive. Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

See More